Biologics & Injectables Index
Convert Unblinded Payer Perceptions into Insights
- Examine Payer Reactions to Healthcare Trends: Analyze how payers respond to key healthcare topics and market developments each quarter to stay ahead of industry shifts.
- Assess Payer Management Strategies: Evaluate payer management techniques, site-of-care trends, and administrative burden via Access Management Topics.
- Review Therapeutic Area Trends and Emerging Therapies: Gain deep insights into specific therapeutic areas, including disruptive market events and payer perceptions of new and emerging therapies.
- Inform Strategy and Market Access Decisions: Access insights from leading payer stakeholders representing 75% of Commercial and Medicare lives.
Track Biologics and Injectables Trends with Confidence
What Our Clients Are Saying
How We Can Help
Harness the power of MMIT’s Biologics & Injectables Index, built on robust field research with an industry-leading panel of pharmacy decision-makers. 100% of panellists are either active P&T participants or control access for pharmaceuticals for their organizations, delivering unparalleled market access visibility and actionable payer perspectives to inform your team’s strategic choices.
The Biologics & Injectables Index helps your team understand payer perspectives and decision‑making by capturing unblinded insights from active P&T participants and access controllers across plans, PBMs, providers, and IDNs, revealing how they evaluate biologic and injectable therapies.
The Biologics & Injectables Index identifies trends in coverage, site‑of‑care dynamics, and emerging therapies by tracking quarterly payer reactions, access management topics, and therapeutic‑area shifts that highlight evolving market dynamics.
The Biologics & Injectables Index informs market access and commercial strategy by providing forward‑looking payer, HCP, and practice‑manager insights that clarify anticipated coverage changes, administration burdens, and competitive pressures across Commercial and Medicare lines of business.
Key Insights From MMIT
Competition, Not Discounts: What’s Shaping Coverage Under Medicare Drug Price Negotiation
8 minutes
Access Now
How Vertical Integration Is Rewriting Biosimilar Strategy
10 minutes
Access Now
Immunology at an Inflection Point: Novel MoAs and the New Payer Standard
10 minutes
Access Now
Solutions to Support Your Strategy
Enhance the Biologics & Injectables Index with related solutions that provide broader visibility into coverage decisions, patient journeys, and emerging therapies. This enables your team to move from insight to confident, informed action.